Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease.

Fiche publication

Date publication

décembre 2024

Journal

Gastro hep advances

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Feagan BG, Panaccione R, Schreiber S, Loftus EV, Peyrin-Biroulet L, Arai T, Lee WJ, Griffith J, Kalabic J, Kligys K, Xuan S, Liao X, Ferrante M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40190340

Résumé

In phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials, risankizumab was shown to benefit symptom and endoscopic defined outcomes in patients with Crohn's disease (CD). We examined the effects of risankizumab on the incidence of CD-related hospitalizations in these studies.